Highlights

  • Control Bionics (ASX:CBL) shares were trading at AUD 0.060, up 3.45% during the afternoon session on 25 August 2026.
  • The company received UK MHRA registration for its NeuroStrip wearable surface electromyography device.
  • The registration enables Control Bionics to pursue commercial Supply across England, Scotland and Wales.
  • Three pilot programs are underway, with additional customer trials expected to begin in September 2026.
  • NeuroStrip is registered as a psychophysiological biofeedback system under GMDN code 63697.

Control Bionics Limited (ASX:CBL) has received registration from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its NeuroStrip wearable surface electromyography device, clearing a key regulatory step for commercial supply in Great Britain.

Control Bionics shares were trading at AUD 0.060, up 3.45% during the afternoon session on 25 August 2026, while the shares remained up 50.00% over the past year.

The UK registration confirms Control Bionics’ status as a registered medical device manufacturer and allows the company to pursue commercial supply and Revenue opportunities across England, Scotland and Wales.

UK Registration

The MHRA registration represents a regulatory milestone for Control Bionics as it advances the commercial rollout of NeuroStrip.

The wearable surface electromyography device is now registered in the Global Medical Device Nomenclature (GMDN) under code 63697 and classified as a psychophysiological biofeedback system.

The registration provides the company with access to pursue commercial activities in the UK market, including potential applications across rehabilitation, research and sports performance sectors.

Market Expansion

Control Bionics identified the UK as a market with established rehabilitation and research sectors, alongside sports performance applications that may utilise NeuroStrip technology.

Following the registration, the company is progressing early user engagement through pilot programs and customer trials.

Three pilot programs are currently underway, with additional customer trials scheduled to commence in September 2026.

Initial users include Dr Tom Maden-Wilkinson from the University of Lancaster and University of Sheffield, the University of Nottingham and British Olympics.

Feedback from these users will contribute to the company’s sales conversion strategy and support its approach to entering the UK market and expanding further across Europe.

NeuroStrip Technology

NeuroStrip is a wearable surface electromyography device designed to capture electrical activity generated by muscles and convert physiological signals into measurable outcomes.

Control Bionics operates a neural-signal technology platform focused on non-invasive applications across multiple areas, including performance, rehabilitation, research and data, and assistive communication.

The company stated that the platform has historically been used in assistive communication and is now being extended into sports performance, rehabilitation, medical research, platform partnerships and broader human-computer interface applications.

The technology does not require surgery or implantation and holds regulatory clearances across the US, Australia and Europe.

Commercial Progress

Control Bionics CEO and Managing Director Jeremy Steele said the UK registration marked another step in the company’s global commercial expansion strategy.

Mr Steele said the UK was a key commercial market for NeuroStrip and that the company was moving from regulatory clearance towards commercial execution.

He added that, together with US FDA registration, the company was building foundations to expand NeuroStrip across international markets.

Company Overview

Control Bionics is a neurotechnology company focused on commercialising non-invasive neural-signal technology developed for clinical and broader market applications.

The company’s technology captures physiological signals, including electrical activity generated by muscles, using medical-grade precision and converts them into decision-ready outcomes.

Control Bionics also operates as a registered NDIS provider in Australia and has developed applications across assistive communication, rehabilitation, research and performance markets.

What Investors May Be Watching

Investors may continue to monitor the progress of NeuroStrip’s UK commercial rollout, including outcomes from ongoing pilot programs and upcoming customer trials.

The company’s next milestones may include further market expansion activities, customer engagement and the development of commercial opportunities following regulatory approvals.